Novo Nordisk has lowered its forecasts for the fourth time. The battle with Pfizer over Metsera continues.
The Danish company faces competition from U.S.-based Lilly. Meanwhile, AstraZeneca is banking on Trump's support.
Astrazeneca buys EsoBiotec for 1 billion. Objective: fight cancer. Negotiations with the US on drug prices
The biotech company is able to genetically modify immune cells, making them capable of attacking tumors directly inside the body in minutes, instead of weeks.
Big Pharma, AstraZeneca grows 19%, Bayer slows
AstraZeneca records total revenues of almost 40 billion thanks to innovative drugs. Improved guidance. Bayer, however, suffers the impact of the weakness of the agricultural division, Ebitda down 25,8%
Astrazeneca: Breast Cancer Drug Trials Disappoint, Stock Price Drops
The experimental drug Astrazeneca used against breast cancer has proven not to work as hoped. The stock, listed in London, is in sharp decline. The goal of 80 billion dollars in revenue by 2030 is further away
AstraZeneca withdraws the Covid-19 vaccine worldwide: here's why
New variants, many vaccines available and increasingly low demand: AstraZeneca decides to withdraw the Vaxzevria vaccine
Pharmaceuticals, the big names are moving: Astrazeneca buys, Pfizer sells. From Recordati increased coupon with an eye on opportunities
Big maneuvers among the big American companies with M&A operations. Meanwhile, the Italian Recordati is thinking about targeted M&A operations in its new plan to 2025
AstraZeneca strengthens its position in oncology therapies and buys the Chinese Gracell for 1,2 billion
Astrazeneca's aim is to strengthen itself in the field of innovative cell therapies for the treatment of cancer and autoimmune diseases
Astrazeneca buys Icosavax vaccines for 1,1 billion. Offered $15 per share
Under the agreement, if some goals are achieved, the premium will also be 91% compared to Monday's close. Vaccines against respiratory viruses will be developed
Astrazeneca will buy the American CinCor Pharma. The deal is worth up to $1,8 billion
The cash portion represents approximately $1,3 billion in transaction value and a 121% premium. The maximum value of the acquisition with the potential exercise of the right would be $1,8 billion and would have a premium…
Astrazeneca acquires TeneoTwo for 1,26 billion and strengthens its anti-cancer treatments
The deal also includes the investigational clinical-stage T-cell treatment, TNB-486, which strengthens the hematologic cancer pipeline.
AstraZeneca, the vaccine inflates revenues: +41% in 2021
Without vaccine revenues, revenues would have risen 26%. Double earnings per core share. AstraZeneca stock runs on the stock exchange
Covid, AstraZeneca: approval requested for new therapy
The Anglo-Swedish company has submitted a new long-acting therapy to the American FDA, 77% effective against the disease: it is valid both as a cure and as an alternative to the vaccine
Astrazeneca, vaccine sales tripled: "No profits from serum"
To date the company has supplied over 1 billion doses to 170 countries - 894 million sales in the second quarter - "No profit from vaccine sales"
Astrazeneca: stop for under 60s who will make calls with Pfizer and Moderna
In the light of the positive data of the epidemiological curve and taking into account the millions of doses of vaccine arriving, the CTS has decided to administer the Oxford vaccine only to the over 60s and continue for the younger ones in…
AstraZeneca, Figliuolo: "We are considering extending it to the under 60s"
After last month's stop, AstraZeneca could again also be administered to the under 60s - "I'm talking about it with ISS and Cts, all vaccines must be used," said Commissioner Figliuolo - Hypothesis of vaccinating students in…
AstraZeneca doubles profit, boom sales of Covid vaccines
The Swedish company also revealed the amount of sales made with the vaccine. Net income rose from $780 million to $1,56 billion in Q68 - Sold 4 million doses of vaccines at $XNUMX each, mostly in…
"AstraZeneca vaccine, giving up is a mistake: that's why"
INTERVIEW with MARIAPIA ABBRACCHIO, pharmacologist and Deputy Pro-Rector of the State University of Milan: "The checks are important but it makes no sense to definitively suspend AZ: to eradicate the virus we need all the weapons". "Herd immunity in 2022, but to return…
Babel vaccines and Italy changes plan: from 2022 only Pfizer and Moderna
AstraZeneca (and probably also J&J) will not be administered to the under 60s, therefore the plans of many countries change. Denmark suspends AstraZeneca definitively. EU-Pfizer agreement for 50 million new doses. The moves of France and Germany
Vaccines: 2 million doses on the way, here is Johnson & Johnson
The decisive week has begun which could give a turning point to the Italian vaccination campaign - The first doses of the Johnson & Johnson single-dose are expected to arrive tomorrow - Here are all the incoming deliveries
The Fed does not touch rates and the markets celebrate
Reading the minutes of the last Fed meeting confirms that the expansionary monetary policy will continue for many more months, while the G20 agreement on the Global minimum tax is expected for July - Only the confusion over Astrazeneca is holding back the European markets…
AstraZeneca vaccine, Ema: "Rare links with thrombosis, but no restrictions"
The vaccine from the Anglo-Swedish company is safe, even if the EMA has added the very rare risk of thrombosis among the possible side effects. Women under 60 are more exposed, but there are no restrictions on administration.
Covid: Veneto, Marche and Trento in orange. The AstraZeneca doses have arrived
The national RT index drops and from 6 April 3 regions are back in orange - In Pratica di Mare 1,3 million Astrazeneca vaccines, distributed to the Regions as early as today - Bookings managed by Poste start in Lombardy
Vaccines, the EU limits exports. New AstraZeneca case
The Commission establishes two new criteria to decide whether the vaccine doses will have to be exported or not: proportionality and reciprocity - Astrazeneca clarifies on the 29 million doses stopped in Anagni
Use on AstraZeneca: "Effective and safe vaccine". EU to stop exports
A US study conducted on 32 volunteers demonstrated 79% efficacy against the Covid-19 disease and 100% against serious cases - FDA to be approved within a month - The EU Council could decide to block the export of…
AstraZeneca vaccine, we start again: the rules in the main Regions
At 15 pm today, the administration of the AstraZeneca vaccine will resume - About 200 vaccinations will have to be recovered - Here is the roadmap established by the main Regions
AstraZeneca, green light from the EMA: safe and effective vaccine
There are 25 suspected cases out of 20 million vaccinated. The administration of the AstraZeneca vaccine is not associated with an increased risk of thrombosis, so the benefits outweigh the risks. Attention remains high to monitor the vaccination campaign in Europe.…
Markets wait in view of the Fed's moves after the new increase in T-Bonds
Great expectations for the intervention of the President of the Fed, Jerome Powell, who, despite the effervescence of US government bonds, is oriented towards confirming the expansive monetary policy without touching interest rates.
Fed and AstraZeneca: the market with bated breath
Great expectations for the words of the president of the Fed, Jerome, Powell, on US rates - But trepidation also for the verdict of the EMA on the AstraZeneca vaccine - T-bonds and German confidence are rising again - Orcel effect on Unicredit…
Stock exchanges dribble AstraZeneca and regain confidence
The growth beyond expectations of the business confidence index in Germany and the sharp recovery of the Nasdaq also give sprint to European stock lists - Piazza Affari rises on the push from the banks - Spreads at 95
AstraZeneca, what happens after the stop? Here is all the information
What should those who already had a reservation do? And for the future? Here are all the doubts, risks and possible solutions, avoiding alarmism. Meanwhile Sweden, Slovenia and Portugal join the list of countries that have blocked via…
The vaccine scares Europe, America is thinking about the holidays
AstraZeneca keeps Europe, including the Stock Exchanges, in suspense, while the States think that the worst is behind them and on Wall Street the stocks of airlines and cruise ships are flying: the Dow Jones is at…
AstraZeneca vaccine, also stopped by Italy, France, Germany and Holland
Both Oxford and the EMA reassure the safety of all vaccines, including the Anglo-Swedish one, but there are now more than a dozen European countries - including ours - which have temporarily and cautiously suspended the administration of the vaccine...
Draghi reassures AstraZeneca and announces a new deviation
The Premier, on a visit to the Fiumicino vaccination hub, talks about the new measures to support families and businesses and announces the request for a new budget gap - On vaccines: "In 11 days the average of vaccinations has doubled, the goal…
Vaccines, AstraZeneca in the crosshairs: it reduces the supply of doses
Nine European countries have blocked the Anglo-Swedish company's drug and in Italy a batch was suspended after 3 suspicious deaths in Sicily. An investigation has been opened, but in the meantime the serum is considered safe by Aifa and the Ministry of Health.
Astrazeneca vaccine: Denmark distances itself
The health authorities of the Scandinavian country have decided to suspend the administration of the vaccine for 14 days, after some cases of thrombosis and pending checks. Stop also in Austria, Norway, the Baltics and Luxembourg. In Italy, Aifa…
Vaccines, EU-Pfizer agreement. All doses arriving for Italy
Signed a contract for an additional 4 million doses of the Pfizer-Biontech vaccine - 532 more doses for Italy - The go-ahead is coming to Johnson and Johnson who denied the cuts - Here are all the doses arriving in Italy
Astrazeneca-Italy: the war on vaccines in 4 points
What is happening between Astrazeneca and Italy? Why did Premier Draghi block the export of vaccines? What will other countries do? Here's everything you need to know.
Vaccines, here are the report cards for effectiveness and ease of use
What are the most effective vaccines in the fight against Covid? And which ones are easier to use? Here is a first evaluation, pending the Johnson & Johnson vaccine
Vaccines: AstraZeneca cuts deliveries again. The EU negotiates
The EU confirms the rumors of Reuters and asks for a new delivery plan from the Anglo-Swedish company. Italian government in the field
Astrazeneca doubles profits in the year of Covid
2020 Revenues Soar 9% to $26,6 Billion - 2021 Earnings Per Share Forecast Expected to Up to $4,75 to $5 $1,9 Dividend per Share - Stock…
Pharmaceuticals on the Stock Exchange: sparks between vaccines, treatments and tests
Between vaccines, treatments and diagnostic tests, pharmaceutical stocks have been within the attention of investors for months. Who earned the most and why?
Vaccines, plan to be redone: prof and over 60 slide
After the delays in Pfizer's deliveries, those of AstraZeneca mess up the vaccination calendar - The Government sues the two pharmaceutical companies: "Enormous damage" - The EU is also moving.
AstraZeneca vaccine: ok from London, but the US and the EU don't trust it
UK will begin administrations from January 4, while the drug agencies of Europe and the United States want to better analyze the effectiveness and methods of use - No one questions the safety of the drug, but there are gray areas
Vaccines: AstraZeneca delayed, plan B is triggered
The first doses of the British pharmaceutical company, expected in January, will not be delivered before late February - To compensate, the supplies arriving from Pfizer and Moderna will be increased
AstraZeneca vaccine: average efficacy at 70%, but 2 advantages
After Pfizer and Moderna, the first results of the experimentation carried out by AstraZeneca in collaboration with Oxford and the IRBM of Pomezia arrive - Vaccine efficacy varies from 62 to 90%, but two advantages over competitors
Vaccine derby: Pfizer re-passes Moderna, waiting for AstraZeneca
It is a battle between the two American giants for the anti Covid vaccine. A new announcement has arrived from Pfizer: "Phase 3 completed, 95% effectiveness. As the derby goes on, a surprise could come from the British AstraZeneca.
Vaccine, a 6-point GDP race starts with Pfizer
AstraZeneca and Johnson & Johnson have anticipated their vaccine will be nonprofit, but Pfizer and others have already set the price. A great deal is foreseen but also an impressive effort for the logistics and distribution of vaccines: from…
Anti-Covid vaccine, first doses by 2020 for IRBM Pomezia
Interviewed by the Financial Lounge, the president of the Irbm research center in Pomezia Piero Di Lorenzo confirmed Prime Minister Conte's announcement: now it's a matter of weeks or a very few months for the vaccine. The real problem will be that of…
Covid vaccine, AstraZeneca resumes experimentation
An independent commission of experts in the United Kingdom has given the green light to the resumption of tests on the anti-Coronavirus vaccine developed by the University of Oxford together with the multinational AstraZeneca and the Italian research center of Pomezia.
Drugs: AstraZeneca sells antibiotic business to Pfizer
AstraZeneca could collect up to 1,6 billion dollars from the operation, also thanks to the rights to the drugs involved
Pharmaceuticals: AstraZeneca buys 55% of Acerta Pharma for 4 billion
AstraZeneca will immediately pay 2,5 billion dollars for the 55% Acerta Pharma stake, while the remainder will be paid after the US authorities allow the new drug to be tested by 2018.
Pfizer denies new offer for Astrazeneca
Pfizer will not make a new offer for the British pharmaceutical giant Astrazeneca: "The offer of May 18 is the definitive one".
AstraZeneca, shareholders want to reopen Pfizer negotiations
The decision of the British pharmaceutical group to say no to a 120 billion dollar offer from Pfizer has not pleased all the shareholders: some are asking for the negotiations to be reopened.
AstraZeneca also rejects Pfizer's third offer
The British pharmaceutical company claims that even the new proposal of the US competitor (which came to offer 117 billion, after the first two attempts at 100 and 106 billion), underestimates the company and its prospects - The AstraZeneca board would be…
Pzifer-Astra Zeneca: here's who will be defeated by the closure of the agreement
While waiting for Pfizer's next move, in the US there is trepidation for the possible umpteenth exit from American soil of one of the country's largest companies - Here are the reasons that push Pfizer to up the ante and who will emerge defeated…
Pfizer, AstraZeneca also rejects the 106 billion offer
"The offer continues to significantly underestimate the value of the company", reads a press release - The British pharmaceutical group also specifies that the new refusal was decided "without hesitation".
AstraZeneca, Pfizer raises offer to 106 billion dollars
In January, the British group rejected an initial offer from Pfizer at 46,61 pounds per share for a total of $99 billion, judging the company "significantly" undervalued.